Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)

Deborah A. Bradley, Stephanie Daignault, Charles J. Ryan, Robert S. DiPaola, Kathleen A. Cooney, David C. Smith, Eric Small, Paul Mathew, Mitchell E. Gross, Mark N. Stein, Alice Chen, Kenneth J. Pienta, June Escara-Wilke, Gerald Doyle, Mahmoud Al-Hawary, Evan T. Keller, Maha Hussain

Research output: Contribution to journalComment/debatepeer-review

Fingerprint Dive into the research topics of 'Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8)'. Together they form a unique fingerprint.